Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, rater-blinded study of mefloquine in progressive multifocal leukoencephalopathy
2008-001314-24Phase 2Completed
- Sponsor
- Biogen
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of mefloquine in progressive multifocal leukoencephalopathy (PML), sponsored by Biogen. Primary endpoint: Change in JC virus DNA levels in CSF. Started May 2008; status: completed.
02
Drugs
mefloquine
03
Conditions
progressive multifocal leukoencephalopathy (PML)
Beyond the preview
Go deeper on 2008-001314-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001314-24.